Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice
Michael Y.T. Chow, Rachel Yoon Kyung Chang, Mengyu Li, Yuncheng Wang, Yu Lin, Sandra Morales, Andrew J. McLachlan, Elizabeth Kutter, Jian Li, Hak‐Kim Chan
Abstract
in the lungs at 16 h. Furthermore, bacterial growth was suppressed in the PEV31-treated group, while the PBS-treated group showed exponential growth. Of the 10 colonies tested, four phage-resistant isolates were observed from the lung homogenates sampled at 24 h after phage treatment. These colonies had a different antibiogram to the parent bacteria. This study provides evidence that pulmonary delivery of phage PEV31 in mice can reduce the MDR bacterial burden.
Topics & Concepts
PharmacokineticsBacteriophageAntibioticsPseudomonas aeruginosaDosingPharmacodynamicsPhage therapyMicrobiologyMedicinePharmacologyBiologyBacteriaEscherichia coliGeneticsBiochemistryGeneBacteriophages and microbial interactionsMonoclonal and Polyclonal Antibodies ResearchAntibiotic Resistance in Bacteria